Could the Gut Provide Early Clues About Parkinson’s Disease?

Scientists are increasingly investigating the relationship between the gut and the brain. This new study, published in Nature Medicine in April 2026, suggests that changes in the community of microorganisms living in the gut—the gut microbiome—may appear before Parkinson’s movement symptoms become evident.

The findings are important because Parkinson’s may begin developing many years before diagnosis. By the time recognisable movement symptoms appear, substantial loss of dopamine-producing brain cells may already have occurred. Finding reliable early markers could eventually help researchers identify people at greater risk and test treatments much earlier.

However, this study has not produced a diagnostic test, and it does not prove that changes in gut bacteria cause Parkinson’s or that altering the microbiome can prevent it.

What did the researchers investigate?

The researchers compared clinical information and stool samples from:

• 271 people diagnosed with Parkinson’s disease
• 43 people carrying a Parkinson’s-associated GBA1 genetic variant but without diagnosed Parkinson’s
• 150 healthy participants without the identified genetic variant

GBA1 variants are among the most common genetic risk factors associated with Parkinson’s. Importantly, carrying one of these variants does not mean a person will necessarily develop the condition. The study notes that only a minority of carriers develop Parkinson’s during their lifetime.

The researchers also compared their findings with three independent datasets from the United States, South Korea and Türkiye, containing an additional 638 people with Parkinson’s and 319 healthy participants.

What did they find?

The researchers identified considerable differences between the gut microbiomes of people with Parkinson’s and healthy participants.

They found 176 microbial species that differed in abundance between the two groups. Together, the changing species represented approximately one-quarter of the gut microbiome examined.

The most interesting finding was that many people carrying a GBA1 variant—but who had not developed Parkinson’s—had a microbiome pattern that sat between the healthy group and the Parkinson’s group.

In simple terms, the pattern appeared to move along a possible continuum:

Healthy microbiome pattern → intermediate pattern in some at-risk people → more pronounced pattern in Parkinson’s

The direction of many of these microbial differences was also found in the independent international datasets, strengthening the evidence that the pattern is not confined to one location or group.

Were the microbiome changes connected with symptoms?

Among people already diagnosed with Parkinson’s, greater microbiome alteration was associated with:

• Longer disease duration
• More severe movement difficulties
• Constipation and autonomic dysfunction
• Depression
• Reduced cognitive and smell function
• A higher burden of non-motor symptoms

Among some genetically at-risk participants, a more Parkinson’s-like microbiome was also associated with subtle motor, autonomic and other possible early symptoms.

The researchers found Parkinson’s-like microbiome patterns in some apparently healthy participants as well. These individuals also tended to have less favourable scores in areas such as diet quality and some motor and non-motor measures.

This raises the possibility that microbiome changes could eventually contribute to identifying people in an early or “prodromal” stage of Parkinson’s—before the condition can be clinically diagnosed.

It does not, however, establish that these healthy participants will go on to develop Parkinson’s.

What does this tell us about the gut–brain connection?

The findings add to evidence that Parkinson’s may not begin in exactly the same way for everyone.

In a proposed “body-first” form of Parkinson’s, early biological changes may begin in the gut or autonomic nervous system before becoming prominent in the brain. Early signs can include constipation, altered sense of smell, urinary problems and REM sleep behaviour disorder.

In a “brain-first” form, changes may begin in the brain before producing substantial gut or autonomic symptoms.

These remain evolving scientific models, but they may help explain why Parkinson’s symptoms and progression vary considerably between individuals.

Does the microbiome cause Parkinson’s?

The study cannot answer this question.

Several possibilities remain:

• Microbiome changes may contribute to Parkinson’s-related processes.
• Early Parkinson’s changes may alter gut function and, in turn, the microbiome.
• Diet, constipation, inflammation, medication, environment and disease processes may interact.
• The microbiome may be an early marker without being a direct cause.
• The relationship may operate in both directions.

The researchers found that the microbiome differences appeared more strongly related to disease duration than to Parkinson’s medication. This is interesting, but it still does not establish cause and effect.

What did the study find about diet?

People with a more Parkinson’s-like microbiome tended to report poorer dietary quality and lower fruit and vegetable intake.

Some potentially anti-inflammatory, butyrate-producing bacteria were less abundant in people with Parkinson’s. Butyrate is a substance produced when certain gut bacteria ferment dietary fibre and is thought to help maintain the gut lining and regulate inflammation.

These findings support further investigation into food quality, fibre and the gut–brain relationship. They do not prove that a particular diet can prevent Parkinson’s or reverse the microbiome pattern.

A diet rich in vegetables, fruit, legumes, wholegrains, nuts and other fibre-containing foods already has broad health benefits. It is reasonable to encourage these foods as part of healthy living, but not to present them as a proven Parkinson’s treatment.

Could a stool test predict Parkinson’s?

Not yet.

The researchers developed an experimental score using 16 microbial species. Within this study, the score helped identify healthy participants whose clinical profile was somewhat closer to that seen in Parkinson’s.

This was a proof-of-concept research tool—not a validated screening or diagnostic test. Before microbiome testing could be used clinically, researchers would need:

• Much larger and more diverse study populations
• Long-term monitoring of people without Parkinson’s
• Evidence showing who does and does not later develop the condition
• Consistent testing and interpretation methods
• Reliable measures of accuracy, including false-positive results
• Evidence that acting on the results improves health outcomes

Commercial microbiome tests should therefore not be interpreted as Parkinson’s risk assessments.

Why this research matters

The study’s real significance is its contribution to earlier detection.

If researchers can eventually combine microbiome information with genetic, clinical and other biological markers, they may become better able to identify people moving towards Parkinson’s before substantial neurological damage has occurred.

That could support:

• Earlier monitoring and clinical support
• Better selection of participants for prevention trials
• More personalised understanding of Parkinson’s subtypes
• Testing treatments before movement symptoms become established
• Future research into whether the microbiome can be safely modified

These are promising possibilities, not options currently available in routine Parkinson’s care.

HEAL takeaway

The gut and brain are deeply connected, and this research provides another important clue about how early Parkinson’s-related changes might be identified.

It does not mean that an unhealthy diet causes Parkinson’s, that people are responsible for developing the condition, or that changing gut bacteria can currently prevent it. Genetics, ageing, environmental exposures and many interacting biological processes may all contribute.

For now, the practical message remains grounded: eating a varied, fibre-rich diet, remaining physically active, managing constipation and seeking medical advice about persistent changes in sleep, smell, movement or autonomic function can support overall health. These actions are worthwhile, but they should not be promoted as a guaranteed way to prevent Parkinson’s.

The hope offered by this research is that earlier detection may eventually create a wider window for intervention—giving science an opportunity to act before Parkinson’s becomes clinically established.

Read the original study in Nature Medicine

A quick note from HEAL: This summary is for general education and does not replace personalised medical advice. Gut symptoms are common and usually have causes unrelated to Parkinson’s. Anyone concerned about new or persistent symptoms should speak with an appropriately qualified health professional.